<unk> , sold under the brand name Cosentyx, is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is marketed by Novartis for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It inhibits a member of the cytokine family, interleukin 17A.
Secukinumab
Emapalumab
Evolocumab
Olaratumab
Sarilumab
Burosumab
Ustekinumab
Avelumab